Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$239.05 USD

239.05
718,021

+4.67 (1.99%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $239.04 -0.01 (0.00%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.

LabCorp (LH) Stock Moves -0.4%: What You Should Know

LabCorp (LH) closed the most recent trading day at $265.73, moving -0.4% from the previous trading session.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Likely to Beat Earnings Estimates

These top-ranked stocks are likely to beat on the bottom line in their next releases.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings

With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.

Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

LabCorp (LH) Gains As Market Dips: What You Should Know

LabCorp (LH) closed at $271.57 in the latest trading session, marking a +0.26% move from the prior day.

Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings

With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.

Walgreens (WBA), Village MD Plan to Expand Into Arizona

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening eight new Village Medical at Walgreens primary care practices in the Tucson area.

LabCorp (LH) Stock Moves -0.42%: What You Should Know

LabCorp (LH) closed the most recent trading day at $270.87, moving -0.42% from the previous trading session.

Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Here's Why You Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.

Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

DaVita's (DVA) New Buyout to Enhance Transplant Experience

DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.

Here's Why You Should Hold SmileDirectClub (SDC) Stock for Now

Investors are optimistic about SmileDirectClub (SDC), backed by its expansion in the teledentistry space and the long-term growth target.

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Quest Diagnostics (DGX) Expands Extended Care With New Buyout

This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.

Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge

Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

Urmimala Biswas headshot

5 Lucrative PEG Stocks for Value Investors

Here are five value stocks, ACI, LH, PSX, FDX and SWRAY, matching our criteria.

QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test

Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.